MedPath

sentinel node biopsy versus limited neck dissection in node negative early oral cancer

Phase 3
Conditions
Health Condition 1: C02- Malignant neoplasm of other and unspecified parts of tongueHealth Condition 2: C00-C14- Malignant neoplasms of lip, oral cavity and pharynx
Registration Number
CTRI/2023/05/052892
Lead Sponsor
A
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1) Age >18 years of age

2) Biopsy-proven invasive squamous cell carcinoma involving the site tongue and buccal

mucosa

3) T1 and T2 lesion as per AJCC TNM 8

th edition

4) Clinicoradiologically node negative

5) Amenable to per oral excision

6) Treatment naïve

7) No other site of malignancy

Exclusion Criteria

1) Previous surgery in the head and neck region,

2) Upper alveolar or palatal lesions

3) Large heterogeneous leukoplakia or other premalignant lesions

4) Previous malignancy in the head and neck region

5) Patients requiring the free flap reconstruction

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
1) Overall survival <br/ ><br>Timepoint: 1) Overall survival 3 years <br/ ><br>
Secondary Outcome Measures
NameTimeMethod
1)Shoulder morbidity (key secondary end point) longitudinally up to 2 years <br/ ><br>2) Disease free survival <br/ ><br>3) Neck nodal recurrence free survival <br/ ><br>4) Other side effects (chyle leak, hematoma, lymphoedema) <br/ ><br>5) Longitudinal Quality of life up to 2 year <br/ ><br>6) Cost effective analysisTimepoint: 1) At baseline before surgery, at 3,6,12 and 24 months after treatment <br/ ><br>2) 3 years <br/ ><br>3) 3 years <br/ ><br>4) intraoperative/ lymphedema at 3,6,12,24 months after treatment <br/ ><br>5) Baseline before surgery, 3,6,12,24 months after treatment <br/ ><br>6)3 years <br/ ><br>
© Copyright 2025. All Rights Reserved by MedPath